The Impact of Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics

Prostate cancer is one of the major cancers of the genitourinary tract. High-mobility group box 1 (HMGB1) was suggested as a promising therapeutic target for prostate cancer. In this study, we aim to elucidate the associations of single nucleotide polymorphisms (SNPs) with prostate cancer susceptibility and clinicopathological characteristics. The SNPs rs1412125, rs2249825, rs1045411, and rs1360485 in 579 prostate cancer patients and 579 cancer-free controls were analyzed with real-time polymerase chain reactions (real-time PCR). All of the data were evaluated with SAS statistical software. Our results showed that the rs1045411 T allele genotype was significantly associated with advanced pathologic T stage (odds ratio (OR) = 1.433, 95% confidence interval (CI) = 1.021‒2.012; = 0.037) and pathologic N1 stage (OR = 2.091, 95% CI = 1.160‒3.767; = 0.012), and the rs1360485 polymorphic CT + TT genotype was associated with pathologic Gleason grade group (4 + 5) (OR = 1.583, 95% CI = 1.017‒2.462; = 0.041), pathologic T stage (3 + 4) (OR = 1.482, 95% CI = 1.061‒2.070; = 0.021), and pathologic N1 stage (OR = 2.131, 95% CI = 1.178‒3.852; = 0.011) compared with their wild-type carriers. In conclusion, our results revealed that the SNPs were associated with the clinical status of prostate cancer. The SNPs may have the potential to predict prostate cancer disease progression.